KneeVoice

KneeVoice is on a mission to enable everyone to understand the health of one of the most prominent joints in the human body—the knee. With its two products, the KneeVoice Diagnostic Device and the KneeVoice Wearable, the company is seeking to distribute its knee monitoring technology to medical professionals and individual consumers around the globe. Initially, the company is focused on U.S. distribution and growth and has already been granted patents for its monitoring technology and diagnostic user interface technology. KneeVoice is seeking additional capital to fund its domestic and eventual international expansion, as it begins rolling out its business-to-business and consumer products. With its technology, KneeVoice hopes that everyone can continuously understand their own joint health and make appropriate life choices to increase the longevity of these vital joints.

None

Filed FDA pre-submission (FDA pre-sub) in January 2022 for its device that monitors cartilage degradation in the knee
Completed clinical trials in several health centers in the U.S and performed ultrasounds on over 3,000 knees in the U.S., Portugal, Spain, Chile, and Colombia with the KneeVoice technology
Granted patents globally that cover the utility of its technology and product designs
Previously raised $1.2+ million from individual investors to develop its knee cartilage assessment technology

Diagnostic Product Inventory: Capital needed to build an inventory for its Diagnostic device (31%)

Wearable Product Inventory: Capital needed to build an inventory for its Wearable device (14%)

Wearable Product Development: Expenses associated with the commercial development of its wearable prototype (11%).

Overhead: General overhead, including payroll costs for programmers and support staff. The company will not use any funds to pay its founders or Directors (11%).

Software: Software development expenses associated with completing its Wearable iOS and Android mobile applications (10%).

Marketing: Expenses associated with digital advertising, trade show participation, and outbound sales efforts (10%).

Legal and Certifications: Fees associated with upkeep and potential future filings to build out its IP portfolio and expenses related to its Diagnostic device certification (8%).

Intermediary Fees: Fees associated paid to the intermediary for this offering (5%).

High Upside, low risk

Investors get SAFEs which can convert into equity during future offerings. KneeVoice's pre-money valuation is $10 million. This company has received patents for its products and is awaiting FDA approval. They've done hundreds of tests on thousands of patients and have a proven product.